Jonas, B. A., Bukari, M., Ferng, T., Jeyakumar, D., Oliai, C., Tanaka, T. N., Huang, C., Socola, F. (2026). A phase 2 study of olutasidenib in combination with azacitidine followed by olutasidenib maintenance after venetoclax plus a hypomethylating agent regimen for IDH1 -mutated acute myeloid leukemia (University of California Hematologic Malignancies Consortium Study 2441).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps6603